Navigation Links
DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Date:5/16/2013

e time and receive event updates.

On behalf of the entire DelMar Pharma team, I thank you for your continued support of our mission to develop and commercialize proven therapies for patients who have failed currently available therapy.  As always, our goal remains to serve to patients who have unmet clinical needs and to build value for our shareholders in the timeliest manner possible.

With warm personal regards,
Jeffrey Bacha, BSc , MBA
President & CEO, DelMar Pharmaceuticals , Inc.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's abi
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... Deprivation and, Chemotherapy Reduced Size of Formerly Resistant Tumors by ... Bavituximab,s Potential to Enhance Multiple ... Regimens for Cancer Therapy -, ATLANTA, and TUSTIN, Calif., ... clinical stage,biopharmaceutical company developing targeted monoclonal antibodies for the,treatment of ...
... Life Sciences, a Roche,company, today announced that researchers at ... implicated in the deaths of,2.4 million honeybee colonies -- ... Sequencer(TM) system. The findings explain how foreign organisms ... sequences of DNA isolated from the bee colonies.,The study, ...
Cached Medicine Technology:Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease 2Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease 3Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease 4Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche 2Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche 3Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche 4
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... a new Medical,Industry Feature of the Week highlighting functional ... maintain healthy digestive flora.,This new programming will be sponsored ... the first and only network for medical professionals,will air ... twice a,day July 7-20. Healthcare professionals can tune in ...
... seeks policy, social changes that boost healthier eating, ... the high rate of obesity in the United States ... Heart Association (AHA) scientific statement. , The AHA also ... adopt healthy behaviors, such as eating right and being ...
... more effective than placebo, one expert says , , MONDAY, ... the pain of placing intravenous (IV) lines in children, ... reduced pain by 34 percent in children getting IV ... the success rate of inserting the lines, said lead ...
... percent of people worldwide suffer from migraines excruciating ... studying a rare, inherited form of migraine, researchers at ... biological basis of the painful, debilitating disorder. , In ... Alfred George Jr., M.D., and colleagues report that ...
... June 30 (HealthDay News) -- The risk of rheumatoid arthritis is ... (more than 10 pounds) than those with an average birth weight ... the Hospital for Special Surgery, New York City, analyzed data from ... Health Study between 1976 and 2002. The women were aged 30 ...
... researchers at the Ocean University of China has developed and ... can accurately measure wind speed and direction over large areas ... weather forecasting and sports. , As described in the ... published by the Optical Society, the mobile lidar station can ...
Cached Medicine News:Health News:ReachMD XM 157 Announces Medical Information Feature on Irritable Bowel Syndrome, Its Treatments, and the Role of Probiotics 2Health News:Population-Based Strategy Urged to Cut U.S. Obesity Rate 2Health News:Spray Cuts Kids' Pain When Getting IVs 2Health News:Migraine mutations reveal clues to biological basis of disorder 2Health News:New technology may help Olympic sailing 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: